<SEC-DOCUMENT>0001641172-25-001487.txt : 20250331
<SEC-HEADER>0001641172-25-001487.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331080021
ACCESSION NUMBER:		0001641172-25-001487
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		25788979

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="margin-top: 0pt; font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
2025</B></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2025, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing today, that the Company has successfully
established that urcosimod (formerly known as OK-101) has been shown to be stable for over two and a half years in single-use ampoules
used for administration of the drug to patients. Urcosimod is presently in a Phase 2b, randomized, placebo-controlled, double-masked,
48-patient clinical trial to treat NCP patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">News Announcement, dated March 31, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT><IMG SRC="ex99-1_001.jpg" ALT="" style="width:200px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Positive Data in Long-Term Stability of Urcosimod</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Urcosimod
                                            in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Urcosimod
                                            stable in single-use ampoules for more than 2&frac12; years</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>FDA
                                            requires drug to show long-term shelf stability for approval</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Daily
                                            administration to patients via ampoules can minimize risk of contamination</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, March 31, 2025. OKYO Pharma Limited (NASDAQ: <U>OKYO</U>), a clinical-stage biopharmaceutical company developing innovative
therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory
dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that the Company has successfully established that urcosimod
(formerly known as OK-101) has been shown to be stable for over two and a half years in single-use ampoules used for administration of
the drug to patients. Urcosimod is presently in a Phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial
to treat NCP patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Success
for a drug in clinical development is not just about clinical data obtained from clinical trials but also requires a considerable amount
of successful effort with what are called the chemistry, manufacturing and controls (CMC) part of a successful submission package to
the FDA,&rdquo; commented Gary S. Jacob, Ph.D., Chief Executive Officer of Okyo Pharma. &ldquo;One of the major requirements for drug
approval is that the drug is stable to degradation for a considerable period of time. This addresses the issue of shelf stability for
a drug, and the fact that we have now established this for urcosimod is a critical positive step in meeting CMC requirements for a successful
New Drug Application (NDA) with FDA.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Recently
completed GMP stability assay testing of single-use ampoules containing urcosimod in ophthalmic solution, stored under refrigerated conditions,
showed impressive stability (0.05% urcosimod &ndash; 94.8% and 0.1% urcosimod &ndash; 97.4%) after over two and a half years,&rdquo;
said Raj Patil, Ph.D., Chief Scientific Officer of OKYO Pharma. &ldquo;We are also conducting long-term stability testing of urcosimod
at room temperature, and so far, the 3-month results at room temperature are at or above 100%. It&rsquo;s important to highlight that
urcosimod is administered to patients as eye drops, and we have been pleased not only with the drop comfort score observed with this
drug but also with the efficacy results from an earlier trial of urcosimod to treat DED. These positive results have fueled our excitement
for this drug&rsquo;s potential to treat NCP.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
marketing of ophthalmic drugs for ocular conditions which typically utilizes small plastic bottles has seen an increasing utilization
of single-use ampoules by patients for ocular conditions such as DED, for ease of use, and for minimizing concerns regarding potential
loss of sterility with use of plastic bottles for daily administration of drug over extended periods of weeks and months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Urcosimod Phase 2b Trial in NCP Patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients are
planned to enroll for the study, with NCP disease confirmed <I>via</I> confocal microscopy. The trial is being conducted as a single-center
trial at Tufts Medical Center and is being led by Pedram Hamrah, MD, of Tufts Medical Center, as Principal Investigator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NCP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal
pain is unknown but is thought to result from nerve damage to the cornea combined with inflammation. Neuropathic corneal pain, which
can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated
by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Urcosimod (Formerly called OK-101)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">Urcosimod
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed
using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has
been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain,
respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially
enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints
in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being
evaluated in </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">a randomized,
placebo-controlled, double-masked Phase 2 trial to treat 48 neuropathic corneal pain patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery
and development of novel molecules to treat neuropathic corneal pain and dry eye disease. In addition to the completed Phase 2 trial
of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients
in a Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">For
further information, please visit </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.okyopharma.com</U><FONT STYLE="color: #1A1A1A">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
(0)20 7495 2379</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A :<# 2(  A$! Q$!_\0
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M Q_Y;M7IOP2\1:SK6O:G%J>IW5W&EJ&59I"P!W#D9KQ&;_72?[QKUO\ 9_\
M^1CU;_KT'_H8K6O&*INR,Z4GSK4^@***X_QU\0M-\%6>'(N-2D7,-JK<_P"\
MWHO\Z\N,7)V1Z#:BKLT_%/BS2_".E-?:E+R>(H%/SRMZ ?UZ"OG+7OBEXHUG
M5)+J'4I[&$\1V]M(55%_J?>N?U_Q#J7B;5)-0U2X,LS< =%0>BCL*TO!O@C5
M/&>H^19IY=M&1Y]TX^2,?U/M7I4Z,*4;R."=651VB7=#U[Q[XCU2+3],UC4Y
MIW/:=@JCU8]A7N47@75!X7:UE\5:H=9;YQ>"X;:K8^Z%S]W]:W/"OA+2O"&E
MK9:;#\QYEG;EY6]2?Z=!6[7)5K<S]U61TTZ5E[S/E?Q!K7CWPSJLFGZGK.I1
M3+]T^>Q5U_O*>XJ#2?B9XKTK4H;LZM<W:(?G@N)"Z..X(/\ ,5])>*_"6E^+
M]*:RU&+Y@"89U'SQ-Z@_S'>OF#Q?X-U3P=JAM;Z/="Q/D7"CY)1[>A]1751J
M0J*S2N<]2$X.Z>A],>#O&NE^,]-^T63[+A //MG/SQG^H]ZZ2OC#1M:U#0-3
MBU#3;EX+B,\,O0CN".X/I7TOX ^)&G^,[46\FVVU:-<R6Y/#_P"TGJ/;J*YJ
MV'<-8[&]*LI:/<[BBBN&\?\ Q)L/!ML;>+9<ZM(N8[<'A/\ :?T'MU-<\8N3
MLC:4E%79K^+_ !GI?@W3#<W\FZ9P?(MD/SRG^@]Z^<]8^)WBK5M3ENUU6XLT
M8_)!;2%40=A[_6N>UG6M0U_4Y=0U*Y>>XE.2S= .P [ >E;W@?P#J7C74-L(
M,%A&?W]TPX7V'JWM^=>E"C"E&\CAG5E4=HFEX5O_ !_XOU5;+3M<U':.99VG
M;9$OJ3_3O7;>(/B='X'A;0-)GFUC4H<BYO[V0NHD[@#/./3H/>N\N[+3?A[\
M/]0.EP^2EM;LP<<L\A& S'N<D5\H.[22,[L69B26)Y)J8*-9MVT14VZ2M?5G
M8WGQ6\9WCDG69(0?X845!^@S6<?'OBPG)\0ZC_W_ &JUX)\ :IXWN)A:/';V
ML&!+<2YP">@ '4UZ(O[/B[1N\0'/?%M_]E6DI48.SM]Q"C5DKH\P_P"$\\5_
M]##J/_?]J/\ A//%?_0PZC_W_:O4?^&?(_\ H8&_\!O_ +*C_AGR/_H8&_\
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M\72I?7N^UT=3S)C#3>R?XU](Z7I5CHNG16&G6Z6]M$,*B#]3ZGWJS"D44")
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M8O\ PB/AO_H Z;_X"I_A1_PB/AO_ * .F_\ @*G^%7]<CV)^K/N?'5%?8O\
MPB/AO_H Z;_X"I_A4D7AG08'#Q:+IR,.A6V0$?I1]<78/JS[GRAH7A/7/$ET
MD&F:=-+NZRE=L:CU+'@5],>"/!L'@OPPUDKB6ZES)<RCHSXZ#V X'_UZZM55
M5"J  .P%*1D8/2N:KB)5--D;TZ*AKU/B2;_7/_O&O6_V?_\ D8]6_P"O0?\
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M=,F,UAIEI:RLNTO#"J$CTR!2K585-;:CITY0TOH:%%%%<QN%>9_'3_DG\?\
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M,#ZCL:^JO#'B"U\4>'[75;0C;,OSIG)C<?>4_0UB>.? UKXC\&C2[2%(I[-
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MQ7"!ESO0@@C!!&WG_P"L**RJ<CE>+T-(<RC:1Z%1116)H%%%% !1110 U_\
M5M]#7AWQ(_UR_4_SHHKKPG\0QK? <'IO_']%_O5]%^$O^/,?0?RHHKKQYSX3
MX3I****\D[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
